1. Home
  2. ARGX vs GIS Comparison

ARGX vs GIS Comparison

Compare ARGX & GIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARGX
  • GIS
  • Stock Information
  • Founded
  • ARGX 2008
  • GIS 1866
  • Country
  • ARGX Netherlands
  • GIS United States
  • Employees
  • ARGX N/A
  • GIS N/A
  • Industry
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • GIS Packaged Foods
  • Sector
  • ARGX Health Care
  • GIS Consumer Staples
  • Exchange
  • ARGX Nasdaq
  • GIS Nasdaq
  • Market Cap
  • ARGX 33.0B
  • GIS 28.0B
  • IPO Year
  • ARGX 2017
  • GIS N/A
  • Fundamental
  • Price
  • ARGX $591.99
  • GIS $51.11
  • Analyst Decision
  • ARGX Strong Buy
  • GIS Hold
  • Analyst Count
  • ARGX 17
  • GIS 15
  • Target Price
  • ARGX $730.07
  • GIS $58.67
  • AVG Volume (30 Days)
  • ARGX 455.0K
  • GIS 6.1M
  • Earning Date
  • ARGX 07-31-2025
  • GIS 09-17-2025
  • Dividend Yield
  • ARGX N/A
  • GIS 4.70%
  • EPS Growth
  • ARGX N/A
  • GIS N/A
  • EPS
  • ARGX 15.94
  • GIS 4.10
  • Revenue
  • ARGX $2,643,062,000.00
  • GIS $19,486,600,000.00
  • Revenue This Year
  • ARGX $61.64
  • GIS N/A
  • Revenue Next Year
  • ARGX $32.00
  • GIS N/A
  • P/E Ratio
  • ARGX $34.02
  • GIS $12.46
  • Revenue Growth
  • ARGX 82.13
  • GIS N/A
  • 52 Week Low
  • ARGX $471.97
  • GIS $49.04
  • 52 Week High
  • ARGX $678.21
  • GIS $75.90
  • Technical
  • Relative Strength Index (RSI)
  • ARGX 63.19
  • GIS 46.50
  • Support Level
  • ARGX $560.91
  • GIS $49.04
  • Resistance Level
  • ARGX $575.48
  • GIS $51.68
  • Average True Range (ATR)
  • ARGX 12.76
  • GIS 1.05
  • MACD
  • ARGX 4.44
  • GIS 0.13
  • Stochastic Oscillator
  • ARGX 95.80
  • GIS 59.65

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

About GIS General Mills Inc.

General Mills is a global packaged food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2025, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.

Share on Social Networks: